



COMMENT

Are we overlooking the lung function in the definition of severe asthma remission?



S. Nolasco^{a,b}, R. Campisi^b, N. Crimi^a, C. Crimi^{a,b,*}

^a Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

^b Respiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, Catania, Italy

Received 4 November 2023; accepted 16 November 2023

Available online 23 December 2023

KEYWORDS

Asthma;
Severe asthma;
Remission;
Lung function

More than a century of research has increased our understanding of the complex immunological pathways underlying asthma airway inflammation.¹ The resulting pharmacological advances and the development of monoclonal antibodies have allowed some patients, even those with the most severe form of the disease, to see their symptoms disappear completely.²

The concept of “remission”, which is already established in fields like rheumatology and oncology, has been embraced as an ambitious but achievable therapeutic goal.³ While there is no universally accepted definition of remission yet, several groups of experts^{3–5} have recently agreed that the remission should be based on a set of clinically relevant composite outcomes (Fig. 1). A fair degree of consensus has been reached about the first three criteria and a specific guide for evaluating treatment response provided; however, this is not the case for the assessment of lung function. Indeed, following a comprehensive literature search, we found that seven definitions have been proposed, but none has achieved wide agreement (Fig. 1).^{6–18}

This heterogeneity resulted in a lack of consistency within the studies that examined remission attainability, producing results which were hardly comparable as the percentage of patients meeting the criteria ranged from 18.3 %¹⁸ to 43.7 %, ¹⁷ thus hindering the research of response predictors. A possible solution might be to exclude lung function from the definition of remission due to its intrinsic volatility, influenced by various confounding factors, such as ethnicity, age, gender, smoking status, BMI and the use of bronchodilators. Nevertheless, the concepts of normalizing and/or stabilizing respiratory function should be considered. Some patients, especially those with a long history of disease, may meet the first three conditions but fail to improve the forced expiratory volume in the first second (FEV₁) due to altered airway architecture secondary to remodeling phenomena.¹⁹ Nonetheless, it has been shown that anti-IL-5 therapies can mitigate the lung function decline in severe eosinophilic asthma patients.²⁰ In this context, a desirable outcome would be to prove that the loss of respiratory function aligns with, or significantly approaches, those of healthy subjects (median –22.4 mL/year in FEV₁ [range 17.7 to 46.4 mL/year], accelerating for each decade of age).²¹ Such

* Corresponding author.

E-mail address: claudia.crimi@unict.it (C. Crimi).

Clinical remission criteria and parameters applied in studies

1. **Absence of asthma exacerbations**³⁻⁵
 - Zero exacerbations for 12 months⁶⁻¹⁸
 2. **Absence of asthma symptoms**³⁻⁵
 - Asthma Control Test (ACT) ≥ 20 or Asthma Control Questionnaire (ACQ) < 1.5 ⁶⁻¹⁸
 3. **No need for systemic corticosteroids for the treatment of asthma**³⁻⁵
 - Prednisone equivalent dose of 0 mg/day⁶⁻¹⁸
 4. **Improved/normalized/stable lung function**³⁻⁵
 - Pre- or post-bronchodilator forced expiratory volume in the first second (FEV₁) $\geq 80\%$ predicted⁶⁻¹³
 - +100 mL increase in pre- or post-bronchodilator FEV₁^{10,14-17}
 - +10% increase in pre- or post-bronchodilator FEV₁¹²
 - Change in pre- or post-bronchodilator FEV₁ not greater than a 5% decline from baseline^{13,18}
 - Change in pre- or post-bronchodilator FEV₁ not greater than a 10% decline from baseline¹³
 - Change in pre- or post-bronchodilator FEV₁ not greater than a 100mL decline from baseline¹⁸
 - FEV₁ \geq lower limit of normal (LLN)¹⁸
- Lung function decline assessment




Fig. 1 Clinical remission criteria, parameters applied in published studies and proposed lung function decline assessment. This figure is an original one by the authors.

functional parameters would support a true disease modification and could potentially serve as a surrogate marker of clinical and biological remission. However, this would require a relatively long-term assessment at different time points since two measurements only may not adequately estimate the rate of lung function decline, and the initial improvement in lung function due to biological therapies tend to gradually decrease after 12 months eventually returning to baseline values in some cases^{22,23}; therefore a 24-month lung function monitoring would be desirable. Indeed, if prevention of lung function deterioration was applied in REDES *post hoc*, after 1 year of anti-IL-5 treatment, 63 % of patients would qualify as having no worsening from baseline in post-bronchodilator FEV₁, a percentage that is likely to be inflated by the relatively short observation period.⁹

Recently, several insightful criteria for lung function “stabilization” have been introduced, namely a change in FEV₁ not greater than a 5 % or 10 % or 100 mL decline from baseline or a FEV₁ greater or equal to the lower limit of normal

(LLN).^{13,18} However, we believe that “stabilization” should be defined with respect to the best value obtained during the first 12 months of therapy rather than compared to baseline since the former would provide a more accurate snapshot of on-treatment decline. More prospective studies assessing pulmonary function decline during biologics are needed, with the challenging ultimate goal of developing specific decline charts, starting from the personal best FEV₁ % achieved after 2 years of therapy, and then followed at least yearly for 5–10 years. In conclusion, how should lung function be assessed within the definition of asthma remission? Since a broad consensus has yet to be reached and studies assessing long-term lung function decline during biologics are lacking, we suggest performing sensitivity analysis using both FEV₁ % ≥ 80 % and +100 mL increase, which are the most commonly used parameters (Fig. 1) to ensure adequate reproducibility. Furthermore, we strongly advise that future studies should include lung function decline, preferably for at least 24 months, using the personal best value obtained during the first 12 months of treatment as a

reference. The ultimate goal should be to provide physicians with a homogeneous and consistent definition that can bridge the gap between clinical and biological remission to enhance accurate outcome prediction and, consequently, focused treatment prescription.

Declaration of Competing Interest

Claudia Crimi has received honoraria for lectures from ResMed, Fisher&Paykel, Sanofi, AstraZeneca, GlaxoSmithKline and Menarini. The other authors declare no conflicts of interest.

CRedit authorship contribution statement

S. Nolasco: Conceptualization, Writing – original draft, Writing – review & editing. **R. Campisi:** Conceptualization, Writing – review & editing, Visualization. **N. Crimi:** Conceptualization, Supervision, Writing – review & editing, Visualization. **C. Crimi:** Conceptualization, Supervision, Writing – review & editing, Visualization.

Role of the funding source

This study was not funded.

References

- Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. *Lancet*. 2023;401(10379):858–73. [https://doi.org/10.1016/S0140-6736\(22\)02125-0](https://doi.org/10.1016/S0140-6736(22)02125-0).
- Lommatzsch M, Brusselle GG, Canonica GW, et al. Disease-modifying anti-asthmatic drugs. *Lancet*. 2022;399(10335):1664–8. [https://doi.org/10.1016/S0140-6736\(22\)00331-2](https://doi.org/10.1016/S0140-6736(22)00331-2).
- Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. *J Allergy Clin Immunol*. 2020;145(3):757–65. <https://doi.org/10.1016/j.jaci.2019.12.006>.
- Blais M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment [published online ahead of print, 2023 Sep 8]. *Ann Allergy Asthma Immunol*. 2023;S1081-1206(23):01218.. <https://doi.org/10.1016/j.anai.2023.08.609>. -8.
- Canonica GW, Blasi F, Carpagnano GE, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus [published online ahead of print, 2023 Aug 7]. *J Allergy Clin Immunol Pract*. 2023;S2213-2198(23):00816.. <https://doi.org/10.1016/j.jaip.2023.07.041>. -4.
- Numata T, Araya J, Okuda K, et al. Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study. *J Asthma Allergy*. 2022;15:1731–41. <https://doi.org/10.2147/JAA.S391807>. Published 2022 Nov 29.
- Maglio A, Vitale C, Pelaia C, et al. Severe asthma remissions induced by biologics targeting IL5/IL5R: results from a multi-center real-life study. *Int J Mol Sci*. 2023;24(3):2455.. <https://doi.org/10.3390/ijms24032455>. Published 2023 Jan 27.
- Oishi K, Hamada K, Murata Y, et al. A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma. *J Clin Med*. 2023;12(8):2900. <https://doi.org/10.3390/jcm12082900>. Published 2023 Apr 16.
- Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. *Front Immunol*. 2023;14:1150162. <https://doi.org/10.3389/fimmu.2023.1150162>. Published 2023 Apr 12.
- Campisi R, Nolasco S, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: a real-world multicentre observational study. *J Clin Med*. 2023;12(12):3953.. <https://doi.org/10.3390/jcm12123953>. Published 2023 Jun 9.
- Sposato B, Bianchi F, Ricci A, Scalese M. Clinical asthma remission obtained with biologics in real life: patients' prevalence and characteristics. *J Pers Med*. 2023;13(6):1020. <https://doi.org/10.3390/jpm13061020>. Published 2023 Jun 20.
- Moermans C, Brion C, Bock G, et al. Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5. *Chest*. 2023;163(6):1368–79. <https://doi.org/10.1016/j.chest.2023.01.037>.
- Thomas D, McDonald VM, Stevens S, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients [published online ahead of print, 2023 Aug 25]. *Allergy*. 2023. <https://doi.org/10.1111/all.15867>. 10.1111/all.15867.
- Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled Post Hoc analysis of the patient journey with benralizumab. *Adv Ther*. 2022;39(5):2065–84. <https://doi.org/10.1007/s12325-022-02098-1>.
- Portacci A, Iorillo I, Quaranta VN, et al. Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: a real-life experience. *Respir Med*. 2023;217:107348. <https://doi.org/10.1016/j.rmed.2023.107348>.
- Milger K, Suhling H, Skowasch D, et al. Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort. *J Allergy Clin Immunol Pract*. 2023;11(9):2701–12. <https://doi.org/10.1016/j.jaip.2023.05.047>. e2.
- Padilla-Galo A, Moya Carmona I, Ausín P, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. *Respir Res*. 2023;24(1):235. <https://doi.org/10.1186/s12931-023-02539-7>. Published 2023 Sep 28.
- McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry [published online ahead of print, 2023 Oct 19]. *Eur Respir J*. 2023;2300819. <https://doi.org/10.1183/13993003.00819-2023>.
- Varricchi G, Ferri S, Pepys J, et al. Biologics and airway remodeling in severe asthma. *Allergy*. 2022;77(12):3538–52. <https://doi.org/10.1111/all.15473>.
- Graff S, Brusselle G, Hanon S, et al. Anti-Interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry. *J Allergy Clin Immunol Pract*. 2022;10(2):467–77. <https://doi.org/10.1016/j.jaip.2021.09.023>.
- Thomas ET, Guppy M, Straus SE, Bell KJL, Glasziou P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. *BMJ Open*. 2019;9(6):e028150. <https://doi.org/10.1136/bmjopen-2018-028150>. Published 2019 Jun 27.
- Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. *J Allergy Clin Immunol*. 2019;143(5):1742–51. <https://doi.org/10.1016/j.jaci.2018.09.033>. e7.
- Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. *Lancet Respir Med*. 2022;10(1):11–25. [https://doi.org/10.1016/S2213-2600\(21\)00322-2](https://doi.org/10.1016/S2213-2600(21)00322-2).